ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation - Concepedia

Concepedia

Publication | Closed Access

ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation

37

Citations

38

References

2018

Year

Christian Goess, Christopher M. Harris, Sara Murdock, Richard McCarthy, Erik R. Sampson, Rachel Twomey, Suzanne Mathieu, Regina Mario, Matthew Perham, Eric R. Goedken,

Modern Rheumatology

Abstract

ABBV-105, a selective BTK inhibitor, demonstrates compelling efficacy in pre-clinical mechanistic models of antibody production and in models of rheumatoid arthritis and lupus.

References

	Year	Citations
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Lee Honigberg, Ashley M. Smith, Mint Sirisawad, Proceedings of the National Academy of Sciences ImmunologyPathologyImmunologic MechanismImmunotherapyHematological Malignancy	2010	1.5K
Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID Mice David J. Rawlings, Douglas C. Saffran, Satoshi Tsukada, Science	1993	866
Defective B cell development and function in Btk-deficient mice Wasif N. Khan, Frederick W. Alt, Rachel M. Gerstein, Immunity Knockout MouseDevelopmental BiologyLymphocyte DevelopmentImmune Cell DevelopmentAdaptive Immune System	1995	724
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin Ulrike Harre, Dan Georgess, Holger Bang, Journal of Clinical Investigation SclerostinAdaptive Immune SystemImmunologyBone RepairOsteoporosis	2012	697
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors Michael S. Cohen, Chao Zhang, Kevan M. Shokat, Science Drug TargetEngineeringMolecular BiologySelectivity FiltersReceptor Tyrosine Kinase	2005	506
Regulation of Btk Function by a Major Autophosphorylation Site Within the SH3 Domain Hyunsun Park, Matthew I. Wahl, Daniel Afar, Immunity Signal TransductionCell RegulationSignaling PathwayNatural SciencesReceptor Tyrosine Kinase	1996	329
Clinical, Immunological, and Molecular Analysis in a Large Cohort of Patients with X-Linked Agammaglobulinemia: An Italian Multicenter Study Alessandro Plebani, Annarosa Soresina, Roberto Rondelli, Clinical Immunology Primary ImmunodeficiencyImmunohematologyX-linked AgammaglobulinemiaAutoimmune DiseaseImmunodeficiencies	2002	326
Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals Masahiro Shinohara, Takako Koga, Kazuo Okamoto, Cell Developmental BiologySignal TransductionBone Morphogenic ProteinReceptor Tyrosine KinaseOsteoarthritis	2008	315
Bruton's Tyrosine Kinase Is Required for Activation of Iκb Kinase and Nuclear Factor κb in Response to B Cell Receptor Engagement James B. Petro, S.M. Jamshedur Rahman, Dean W. Ballard, The Journal of Experimental Medicine	2000	300
IFN-α Induces Early Lethal Lupus in Preautoimmune (New Zealand Black × New Zealand White)F1 but Not in BALB/c Mice Alexis Mathian, Arthur G. Weinberg, Mike Gallegos, The Journal of Immunology	2005	265

Page 1